Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:3024-3027

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daoud, E. G.
Right arrow Articles by Morady, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daoud, E. G.
Right arrow Articles by Morady, F.
Related Collections
Right arrow Electrophysiology
Right arrow Cardiovascular Pharmacology
Right arrow Echocardiography

(Circulation. 1999;99:3024-3027.)
© 1999 American Heart Association, Inc.


Clinical Investigation and Reports

Short-Term Effect of Atrial Fibrillation on Atrial Contractile Function in Humans

Emile G. Daoud, MD; Pamela Marcovitz, MD; Bradley P. Knight, MD; Rajiva Goyal, MD; K. Ching Man, DO; S. Adam Strickberger, MD; William F. Armstrong, MD; Fred Morady, MD

From the Division of Cardiology, Department of Internal Medicine, University of Michigan Hospital, Ann Arbor, Mich.

Correspondence to Emile Daoud, MD, Mid-Ohio Cardiology Research, 3545 Olentangy River Rd, Room 325, Columbus, OH 43214.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Conversion of chronic atrial fibrillation (AF) is associated with atrial stunning, but the short-term effect of a brief episode of AF on left atrial appendage (LAA) emptying velocity is unknown. The purpose of this study was to determine whether a short episode of AF affects left atrial function and whether verapamil modifies this effect.

Methods and Results—The subjects of this study were 19 patients without structural heart disease undergoing an electrophysiology procedure. In 13 patients, LAA emptying velocity was measured by transesophageal echocardiography in the setting of pharmacological autonomic blockade before, during, and after a short episode of AF. During sinus rhythm, the baseline LAA emptying velocity was measured 5 times and averaged. AF was then induced by rapid right atrial pacing. After either spontaneous or electrical conversion, LAA emptying velocity was measured immediately on resumption of sinus rhythm and every minute thereafter. The mean duration of AF was 15.3±3.8 minutes. The mean baseline emptying velocity was 70±20 cm/s. The first post-AF emptying velocity was 63±20 cm/s (P=0.02 versus baseline emptying velocity). The post-AF emptying velocity returned to the baseline emptying velocity value after 3.0 minutes. The mean percent reduction in post-AF emptying velocity was 9.7±21% (range, 15% increase to 56% decrease). A second group of 6 patients were pretreated with verapamil (0.1-mg/kg IV bolus followed by an infusion of 0.005 mg · kg-1 · min-1). In these patients, the first post-AF emptying velocity, 58±14 cm/s, was not significantly different from the pre-AF emptying velocity, 60±13 cm/s (P=0.08).

Conclusions—In humans, several minutes of AF may be sufficient to induce atrial contractile dysfunction after cardioversion. When atrial contractile dysfunction occurs, there is recovery of AF within several minutes. AF-induced contractile dysfunction is attenuated by verapamil and may be at least partially mediated by cellular calcium overload.


Key Words: contractility • calcium • verapamil • echocardiography


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Previous clinical studies have demonstrated left atrial appendage (LAA) contractile dysfunction after cardioversion of AF and have identified clinical and echocardiographic features associated with contractile dysfunction, including the duration of atrial fibrillation (AF).1 2 3 4 5 6 7 8 A study of pacing-induced AF in pigs demonstrated that a brief episode of AF induces acute atrial contractile dysfunction and that this can be blunted by verapamil.9 However, no prior studies have assessed the short-term effect of a brief episode of AF on left atrial contractility in humans or the effect of pretreatment with verapamil. Therefore, the purpose of this study was to measure the effect of pacing-induced AF on the LAA emptying velocity in patients and to determine whether verapamil modifies this effect.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Characteristics of the Study Population
The subjects of this study were 19 patients referred to the University of Michigan Hospital for radiofrequency catheter ablation of paroxysmal supraventricular tachycardia. Exclusion criteria consisted of an unwillingness to provide informed consent; a baseline rhythm of AF, atrial flutter, or atrial tachycardia; a contraindication to the use of propranolol or atropine; the presence of structural heart disease as determined by a transthoracic echocardiogram; the inability to induce AF by pacing; concurrent treatment with a calcium channel antagonist; or the inability to perform a transesophageal echocardiogram or to visualize the LAA. Among the 202 patients screened, 19 patients (9%) satisfied all criteria. There were 7 men and 12 women; their age was 43±13 years (mean±SD); and their mean left ventricular ejection fraction was 0.62±0.05.

Electrophysiological Testing
All antiarrhythmic drug therapy was discontinued >=5 half-lives before the procedure. After informed consent was obtained, three 7-F sheaths were placed in a femoral vein, and 3 quadripolar electrode catheters were positioned in the high right atrium, His bundle position, and right ventricular apex. Patients were sedated with intravenous midazolam and fentanyl and received 3000 U heparin IV. Leads V1, I, II, and III and intracardiac electrograms were recorded (Mingograph 7, Siemens-Elema AB). Pacing was performed with a programmable stimulator (Bloom Associates, LTD).

Study Protocol
The study protocol, approved by the Human Research Committee, was performed after completion of the clinically indicated portion of the electrophysiology procedure. A quadripolar electrode catheter was positioned in the right atrial appendage. The mean atrial capture threshold was 0.8±0.2 mA. Autonomic blockade was achieved by infusion of atropine (0.04 mg/kg) and propranolol (0.2 mg/kg) over {approx}5 minutes.10 The mean patient weight was 82±18 kg, and the mean atropine and propranolol dosages were 3.5±0.7 and 15.3±3.5 mg, respectively.

Transesophageal echocardiography was performed in the electrophysiology laboratory by use of a 5.0-MHz phased-array biplane or multiplane transducer and a commercially available system (model 2500, Hewlett-Packard Co, or model UM9-OPT2, Advanced Technology Laboratories). In addition to the intravenous sedatives administered during the electrophysiology procedure, benzocaine 20% and lidocaine 10% topical spray were used to anesthetize the oropharynx. The transesophageal echocardiography probe was inserted into the esophagus, and the LAA was visualized. LAA peak flow emptying velocity was measured with pulsed Doppler by placing the sample volume {approx}1 cm into the mouth of the atrial appendage. The emptying velocity was determined by averaging 5 consecutive cardiac cycles during sinus rhythm and 10 cycles during AF. The emptying velocity was measured in sinus rhythm before induction of AF. AF was then induced by bursts of right atrial pacing. The mean emptying velocity during AF was 52±21 cm/s. In 3 patients, the transesophageal probe was removed for the first 10 minutes of AF because of persistent coughing. In these 3 patients, the probe was reinserted, and each patient tolerated the second intubation without discomfort or coughing. In every patient, the transesophageal probe was in proper imaging position at the time of conversion of AF to sinus rhythm.

In 13 patients, the study protocol was performed without pretreatment with verapamil. In this group of patients, there were no significant differences between the baseline and post-AF sinus cycle length (602±50 versus 593±75 ms, P=0.4), or atrial-His interval (75±13 versus 78±14 ms, P=0.7). Intravenous verapamil was administered after autonomic blockade and before induction of AF in a second group of 6 consecutive patients. Verapamil was administered at a dosage of 0.1 mg/kg over {approx}2 minutes. An infusion of 0.005 mg · kg-1 · min-1 verapamil was started 3 minutes later and continued until the protocol was completed.11 12 13 14 The mean total verapamil dosage was 16.4±2.8 mg administered over 27.4±3.5 minutes. In these 6 patients, the post-AF sinus cycle length (785±109 ms) and atrial-His interval (96±27 ms) were the same as or longer than before verapamil (sinus cycle length, 735±79 ms, P=0.10; atrial-His interval, 87±15 ms, P=0.02).

After either spontaneous cardioversion in 8 patients or electrical cardioversion in 11 patients in whom AF persisted >15 minutes, the post-AF emptying velocity was measured on resumption of sinus rhythm and at subsequent 1-minute intervals until the emptying velocity returned to the baseline emptying velocity value.

Statistical Analysis
Continuous variables are expressed as mean±SD. Continuous variables were compared with a t test, and categorical variables were compared by {chi}2 analysis. Linear interpolation of the plotted serial measurement data was used to generate data for analysis of temporal changes of the emptying velocity.15 16 A value of P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Pre-AF and Post-AF Emptying Velocity in the Absence of Verapamil
Among the 13 patients who did not receive verapamil, LAA emptying velocity before induction of AF was 70±20 cm/s. The duration of induced AF, inclusive of the time required for atrial pacing, was 15.3±3.8 minutes (range, 14.75 to 19.5 minutes). Post-AF emptying velocity was measured an average of 9 times per patient (Table 1Down). The emptying velocity immediately after conversion of AF was 63±20 cm/s (P=0.02 versus baseline emptying velocity). The mean percent reduction in the first post-AF emptying velocity was 9.7±21% (range, 15% increase to 56% decrease). Post-AF emptying velocity was significantly less than the baseline emptying velocity for 3.0 minutes after conversion of AF (the FigureDown).


View this table:
[in this window]
[in a new window]
 
Table 1. Change in LAA Emptying Velocity After Pacing-Induced AF



View larger version (23K):
[in this window]
[in a new window]
 
Figure 1. Temporal recovery of post-AF LAA emptying velocity. Mean emptying velocities are plotted against time after conversion of pacing-induced AF. There is significant reduction in emptying velocity after conversion of AF, with recovery by 3 minutes in patients not pretreated with verapamil ({diamondsuit}). There is no significant difference between pre-AF emptying velocity compared with post-AF emptying velocities in patients pretreated with intravenous verapamil ({triangleup}). *P<0.05 vs pre-AF.

A >=15% reduction in the post-AF emptying velocity occurred in 5 of 13 patients (38%). In these patients, the baseline emptying velocity was 64±21 cm/s, and the first post-AF emptying velocity was 42±18 cm/s (P<0.01). The mean percent decrease in emptying velocity was 32±13%, and post-AF emptying velocity remained significantly less than the baseline emptying velocity for 4.0±0.6 minutes. Spontaneous echocardiographic contrast was not observed in any patient.

The percent change in the first post-AF emptying velocity compared with baseline atrial emptying velocity did not correlate with the duration of pacing-induced AF (P=0.4, r=0.2). There also was no significant difference in the mean percent change in the first post-AF emptying velocity in patients requiring electrical cardioversion compared with patients in whom AF converted spontaneously (P=0.3).

Pre- and Post-AF Emptying Velocities After Pretreatment With Verapamil
Among the 6 patients pretreated with verapamil, LAA emptying velocity before induction of AF was 60±13 cm/s. This emptying velocity was significantly less than the pre-AF emptying velocity for those patients who did not receive verapamil (70±20 cm/s, P<0.001). The duration of induced AF, inclusive of the time required for atrial pacing, was 16.4±2.4 minutes (range, 15.2 to 18.75 minutes). Post-AF emptying velocity was measured an average of 9 times per patient (Table 2Down). The emptying velocity immediately after conversion of AF was 58±14 cm/s (P=0.08 versus baseline emptying velocity). There were no serial changes in LAA emptying velocity after conversion of AF (the FigureUp).


View this table:
[in this window]
[in a new window]
 
Table 2. Change in LAA Emptying Velocity After Pretreatment With Intravenous Verapamil and Pacing-Induced AF

The percent change in the first post-AF emptying velocity compared with the baseline atrial emptying velocity did not correlate with the duration of the pacing-induced AF (P=0.8, r=0.1). There also was no significant difference in the mean percent change in the first post-AF emptying velocity in patients requiring electrical cardioversion compared with patients in whom AF converted spontaneously (P=0.1).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Main Findings
The main findings of this study are that pacing-induced AF significantly reduces the LAA emptying velocity on resumption of sinus rhythm, that this reduction occurs after only {approx}15 minutes of AF, that temporal recovery of the contractile dysfunction occurs within a few minutes, and that pretreatment with verapamil prevents this AF-induced contractile dysfunction.

Possible Mechanisms
The rapid onset of reduced atrial contractility and the rapid recovery of LAA mechanical function found in this study after only a brief episode of AF imply that metabolic changes were responsible. Frequent17 18 19 and irregular20 depolarization of atrial myocytes during AF results in elevation of cytosolic calcium.9 The absence of AF-induced contractile dysfunction in patients pretreated with verapamil suggests that AF-induced cytosolic calcium overload may mediate this acute dysfunction.

Two experimental studies support the hypothesis that acute contractile dysfunction may be related to cellular calcium overload. The first study demonstrated in a Langendorff-perfused ferret heart that transient exposure to high intracellular calcium concentration results in decreased contractile responsiveness to calcium.21 A possible mechanism by which calcium overload may diminish the sensitivity of myofilaments to calcium is through activation of protein kinase C, which may interfere with myofilament responsiveness.21

In a second study, in an open-chest pig model of pacing-induced AF, Leistad et al9 assessed the short-term effect of a 5-minute episode of AF on left atrial systolic shortening. Similar to the findings of the present study, there was a 29% reduction in atrial contractile function after AF, and this peak reduction occurred by 15 seconds after restoration of sinus rhythm and returned to baseline after {approx}5 minutes. Furthermore, left atrial systolic shortening was exacerbated by the calcium agonist BAY K8644 and attenuated by the calcium antagonist verapamil. The findings of the present study extend the results of experimental studies to humans and suggest that acute atrial contractile dysfunction is mediated by AF-induced changes in intracellular calcium concentration.

Of note is that the pre-AF emptying velocity was significantly less in patients who received verapamil compared with the patients in this study who did not receive verapamil. This finding may reflect the negative inotropic effect of calcium channel blockade but does not negate the main finding that pretreatment with verapamil prevented AF-induced contractile dysfunction.

Previous Clinical Studies
Several clinical studies have assessed LAA mechanics after cardioversion of AF.1 2 3 4 5 6 The major limitations of these studies were that there was no assessment of LAA function before the onset of AF and that the duration of AF was poorly defined. The present study is unique in that the duration of AF was timed and the LAA emptying velocity could be measured immediately before, during, and for several minutes after AF conversion.

A second feature of this study is that LAA dysfunction was defined as a reduction relative to the baseline emptying velocity. This definition has not been the conventional criterion for "atrial stunning." Conventionally, atrial stunning refers to a reduction in atrial appendage contractile function after conversion of AF compared with the contractile function during AF before cardioversion.1 2 3 4 5 6 If this definition of stunning had been used in the present study, no contractile dysfunction would have been recognized, because the mean emptying velocity during AF (52±21 cm/s) was less than the emptying velocity after conversion. Therefore, future studies assessing atrial contractile dysfunction and its recovery should compare contractile function immediately after AF conversion to contractile function measured in sinus rhythm at a later time, after maximum recovery.

Autonomic Tone
Induction and conversion of AF are likely to heighten sympathetic tone, and this may mask or minimize AF-induced acute atrial dysfunction. To minimize the influence of autonomic tone and to assess the independent effect of AF on emptying velocity, atropine and propranolol were administered before induction of AF. A constant degree of autonomic blockade was confirmed by the absence of any significant differences in sinus cycle length or atrial-His interval before and after completion of the study protocol in those patients who did not receive verapamil.

Study Limitations
A limitation of this study is that the findings may be specific only to pacing-induced AF in subjects with structurally normal atria and may not apply to spontaneous episodes of AF or in patients with structurally abnormal atria. A second limitation is the small sample size. Although 202 patients were screened, the protocol was performed in only 9%. This low percentage largely reflects the reluctance of patients to consent to a transesophageal echocardiogram that was not clinically indicated. A third limitation is that the absence of change in post-AF emptying velocity in the verapamil group may have resulted because verapamil masked rather than prevented such a change. However, the different response to AF in the control versus verapamil group is strong evidence that calcium channel blockade is at least partly responsible for prevention of AF-induced contractile dysfunction.

Conclusions
Experimental and clinical investigations suggest that intracellular calcium overload contributes to AF-induced electrical remodeling and promotes recurrence of AF.22 23 24 25 The results of this study imply that calcium overload may also be partly responsible for AF-induced atrial mechanical dysfunction. Rapid17 18 19 and irregular20 depolarization of atrial myocytes as a result of AF results in elevation of cytosolic calcium. This increase in cellular calcium concentration may then serve as the common mediator of AF-induced electrical remodeling (by shortening the atrial refractory period) and AF-induced contractile dysfunction. Administration of intravenous verapamil before induction of AF has been reported to prevent electrical remodeling,22 and the findings of this study imply that pretreatment with verapamil can also prevent AF-induced reduction in LAA emptying velocity. Whether the use of verapamil before cardioversion of spontaneous episodes of persistent AF will blunt postcardioversion contractile dysfunction remains to be determined.

Received December 31, 1998; revision received March 16, 1999; accepted March 29, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Grimm RA, Stewart WJ, Maloney JD, Cohen GI, Pearce GL, Salcedo EE, Klein AL. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359–1366.[Abstract]

2. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994;23:1535–1540.[Abstract]

3. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307–316.[Abstract]

4. Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol. 1994;23:599–607.[Abstract]

5. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol. 1996;78:435–439.[Medline] [Order article via Infotrieve]

6. Harjai KJ, Mobarek SK, Cheirif J, Boulos LM, Murgo JP, Abi-Samra F. Clinical variables affecting recovery of left atrial mechanical function after cardioversion from atrial fibrillation. J Am Coll Cardiol. 1997;30:481–486.[Abstract]

7. Rubin DN, Katz SE, Riley MF, Douglas PS, Manning WJ. Evaluation of left atrial appendage anatomy and function in recent-onset atrial fibrillation by transesophageal echocardiography. Am J Cardiol. 1996;78:774–778.[Medline] [Order article via Infotrieve]

8. Hwang JJ, Li YH, Lin JM, Wang TL, Shyu KG, Ko YL, Lin JL, Chen JJ, Kuan P, Lien WP. Left atrial appendage function determined by transesophageal echocardiography in patients with rheumatic mitral valve disease. Cardiology. 1994;85:121–128.[Medline] [Order article via Infotrieve]

9. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation. 1996;93:1747–1754.[Abstract/Free Full Text]

10. Jose AD, Taylor RR. Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. J Clin Invest. 1969;48:2019–2031.

11. Hart LL, Middleton RK, McQueen KD. Continuous verapamil infusion. Ann Pharmacother. 1989;23:1005–1006.[Medline] [Order article via Infotrieve]

12. Reiter MJ, Shand DG, Aanonsen LA, Wagoner R, McCarthy E, Pritchett ELC. Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. Am J Cardiol. 1982;50:716–721.[Medline] [Order article via Infotrieve]

13. Wagner JG, Rocchini AP, Vasiliades J. Prediction of steady-state verapamil plasma concentrations in children and adults. Clin Pharmacol Ther. 1982;32:172–181.[Medline] [Order article via Infotrieve]

14. Barbarash RA, Bauman JL, Lukazewski AA, Srebro JP, Rich S. Verapamil infusions in the treatment of atrial tachyarrhythmias. Crit Care Med. 1986;14:886–888.[Medline] [Order article via Infotrieve]

15. Gans DJ. A simple method based on broken-line interpolation for displaying data from long-term clinical trials. Stat Med. 1982;1:131–137.[Medline] [Order article via Infotrieve]

16. Schluchter MD. Analysis of incomplete multivariate data using linear models with structured covariance matrices. Stat Med. 1988;7:317–324.[Medline] [Order article via Infotrieve]

17. Lee H-C, Clusin WT. Cytosolic calcium staircase in cultured myocardial cells. Circ Res. 1987;61:934–939.[Abstract/Free Full Text]

18. Schouten VJA, Morad M. Regulation of Ca2+ current in frog ventricular myocytes by the holding potential, c-AMP and frequency. Pflugers Arch. 1989;415:1–11.[Medline] [Order article via Infotrieve]

19. Thandroyen FT, Morris AC, Hagler HK, Ziman B, Pai L, Willerson JT, Buja LM. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res. 1991;69:810–819.[Abstract/Free Full Text]

20. Wier WG, Yue DT. Intra-cellular calcium transients underlying the short-term force-interval relationship in ferret ventricular myocardium. J Physiol (Lond). 1986;376:507–530.[Abstract/Free Full Text]

21. Kitakaze M, Weisman HF, Marban E. Contractile dysfunction and ATP depletion after transient calcium overload in perfused ferret hearts. Circulation. 1988;77:685–695.[Abstract/Free Full Text]

22. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, Strickberger SA, Morady F. Effect of verapamil and procainamide on atrial fibrillation–induced electrical remodeling in humans. Circulation. 1997;96:1542–1550.[Abstract/Free Full Text]

23. Tieleman RG, Van Gelder IC, Crijns HJ, DeKam PJ, Van Den Berg MP, Haaksma J, Van Der Woude HJ, Allessie MA. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31:167–173.[Abstract/Free Full Text]

24. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94:2968–2974.[Abstract/Free Full Text]

25. Tielman RG, De Langen C, Van Gelder IC, DeKam PJ, Grandjean J, Bel KJ, Wijffels MC, Allessie MA, Crijns HJ. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997;95:1945–1953.The purpose of this study was to assess the short-term change in left atrial appendage (LAA) emptying velocity after a brief episode of pacing-induced atrial fibrillation (AF) and to assess the effect of pretreatment with intravenous verapamil. In 13 patients, the baseline LAA emptying velocity was measured and AF was induced by pacing. The duration of AF was 15.3±3.8 minutes. The baseline LAA emptying velocity was 70±20 cm/s, and the first post-AF emptying velocity was 63±20 cm/s (P=0.02). The emptying velocity gradually returned to baseline over 3 minutes. In 6 other patients, verapamil was administered before the induction of AF, and there was no significant difference between the post-AF and pre-AF emptying velocities. In conclusion, a brief episode of pacing-induced AF may cause transient atrial contractile dysfunction, and this effect is blunted by pretreatment with verapamil.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
NEJMHome page
The GISSI-AF Investigators
Valsartan for Prevention of Recurrent Atrial Fibrillation
N. Engl. J. Med., April 16, 2009; 360(16): 1606 - 1617.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
N. Dagres, G. Karatasakis, F. Panou, G. Athanassopoulos, T. Maounis, E. Tsougos, K. Kourea, I. Malakos, D. Th. Kremastinos, and D. V. Cokkinos
Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation
Eur. Heart J., September 1, 2006; 27(17): 2062 - 2068.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
G. D. Veenhuyzen, C. S. Simpson, and H. Abdollah
Atrial fibrillation
Can. Med. Assoc. J., September 28, 2004; 171(7): 755 - 760.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M Brundel, H. H Kampinga, and R. H Henning
Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation
Cardiovasc Res, June 1, 2004; 62(3): 521 - 528.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. Schotten, M. Duytschaever, J. Ausma, S. Eijsbouts, H.-R. Neuberger, and M. Allessie
Electrical and Contractile Remodeling During the First Days of Atrial Fibrillation Go Hand in Hand
Circulation, March 18, 2003; 107(10): 1433 - 1439.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Allessie, J. Ausma, and U. Schotten
Electrical, contractile and structural remodeling during atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 230 - 246.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M. Brundel, R. H. Henning, H. H. Kampinga, I. C. Van Gelder, and H. J.G.M. Crijns
Molecular mechanisms of remodeling in human atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 315 - 324.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M Brundel, J. Ausma, I. C van Gelder, J. J.L Van Der Want, W. H van Gilst, H. J.G.M Crijns, and R. H Henning
Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 380 - 389.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. L.J.L Thijssen, H. M.W van der Velden, E. P van Ankeren, J. Ausma, M. A Allessie, M. Borgers, G. J.J.M van Eys, and H. J Jongsma
Analysis of altered gene expression during sustained atrial fibrillation in the goat
Cardiovasc Res, May 1, 2002; 54(2): 427 - 437.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Kurita, H. Mitamura, A. Shiroshita-Takeshita, A. Yamane, M. Ieda, O. Kinebuchi, T. Sato, S. Miyoshi, M. Hara, S. Takatsuki, et al.
Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling
Cardiovasc Res, May 1, 2002; 54(2): 447 - 455.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
U. Schotten, M. Greiser, D. Benke, K. Buerkel, B. Ehrenteidt, C. Stellbrink, J. F Vazquez-Jimenez, F. Schoendube, P. Hanrath, and M. Allessie
Atrial fibrillation-induced atrial contractile dysfunction: a tachycardiomyopathy of a different sort
Cardiovasc Res, January 1, 2002; 53(1): 192 - 201.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923.
[PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. L.J.L. Thijssen, J. Ausma, and M. Borgers
Structural remodelling during chronic atrial fibrillation: act of programmed cell survival
Cardiovasc Res, October 1, 2001; 52(1): 14 - 24.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
N.M. Al-Saady and M. Sopher
Prothrombotic markers in atrial fibrillation: what is new?
Eur. Heart J., September 2, 2001; 22(18): 1635 - 1639.
[PDF]


Home page
Eur Heart JHome page
F.L Li-Saw-Hee, A.D Blann, D Gurney, and G.Y.H Lip
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function
Eur. Heart J., September 2, 2001; 22(18): 1741 - 1747.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
H. Sun, D. Chartier, N. Leblanc, and S. Nattel
Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes
Cardiovasc Res, March 1, 2001; 49(4): 751 - 761.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Fareh, A. Benardeau, and S. Nattel
Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs
Cardiovasc Res, March 1, 2001; 49(4): 762 - 770.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. T. Altemose, D. P. Zipes, J. Weksler, J. M. Miller, and J. E. Olgin
Inhibition of the Na+/H+ Exchanger Delays the Development of Rapid Pacing-Induced Atrial Contractile Dysfunction
Circulation, February 6, 2001; 103(5): 762 - 768.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. A. Khan
Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation
J. Am. Coll. Cardiol., February 1, 2001; 37(2): 542 - 547.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. S. Friedman, M. Win, A. Hussain, and A. Sinha
Effects of Cardiac Glycosides on Atrial Contractile Dysfunction After Short-term Atrial Fibrillation
Chest, October 1, 2000; 118(4): 1116 - 1126.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daoud, E. G.
Right arrow Articles by Morady, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daoud, E. G.
Right arrow Articles by Morady, F.
Related Collections
Right arrow Electrophysiology
Right arrow Cardiovascular Pharmacology
Right arrow Echocardiography